Table 1 Patient Characteristics

Median age, years

51.0

53.8

52.6

T stage

   T1-T2

126

74.1

178

75.1

304

74.7

   T3-T4

40

23.5

51

21.5

91

22.4

   Unknown

4

2.4

8

3.4

12

2.9

No. of axillary nodes involved

   ≤3 nodes

96

56.5

139

58.6

235

57.7

   >3 nodes

70

41.2

80

33.8

150

36.9

   Unknown

4

2.4

8

3.4

12

2.9

Hormonal status

   Negative

75

44.1

70

29.5

145

35.6

   Positive

95

55.9

167*

70.5

262

64.4

HER-2 status

   Negative

126

74.1

177

74.7

303

74.4

   Positive

44

25.9

60

25.3

104

25.6

Subtype

   HR + and HER-2 -

72

42.4

133*

56.1

205

50.4

   HR + and HER-2 +

23

13.5

34

14.3

57

14.0

   HR - and HER-2 +

21

12.4

26

11.0

47

11.5

   HR - and HER-2 -

54

31.8

44*

18.6

98

24.1

Relapse Free Interval

   ≤ 2 yr

81

47.6

84*

35.4

165

40.5

   >2 yr

89

52.4

153

64.6

242

59.5

Site of first recurrence

   non visceral

77

45.3

124

52.3

201

49.4

   visceral

93

54.7

113

47.7

206

50.6

Brain metastasis at diagnosis

   no

163

95.9

224

94.5

387

95.1

   yes

6

3.5

12

13.0

18

4.4

Adjuvant chemotherapy

   no

59

34.7

65

27.4

124

30.5

   yes

111

65.3

172

72.6

283

69.5

Adjunvant endocrine therapy

   no

80

47.1

92

38.8

172

42.3

   yes

90

52.9

145

61.2

235

57.7